Antibiotic Utilization Patterns and Adverse Drug Events Risk in Special Populations: A Comprehensive Review

Shaji A, Regin A, Sunny A, Aparna A, Lakshmanan S, Reddy KP, Vinod KR

WJMER

World Journal of Medical Education and Research

An Official Publication of the Education and Research Division of Doctors Academy



DOCTORS ACADEMY

BETTER EDUCATION. BETTER HEALTH.

ISSN 2052-1715

World Journal of Medical Education and Research:
An Official Publication of the Education and Research Division of Doctors Academy

Review Article
DAUIN 20260235

Antibiotic Utilization Patterns and Adverse Drug Events Risk in Special Populations : A Comprehensive Review

Shaji A[I], Regin A[I], Sunny A[I], Aparna A[I], Lakshmanan S[I], Reddy KP[I], Vinod KR[I]

Institution
[I] *Sanjo College of Pharmaceutical Studies, Vellapara, Chithali (Post), Kuzhalmannam, Palakkad – 678702, Kerala, India.*

WJMER, Vol 33: Issue 1, 2026

Abstract:
Antimicrobials are among the most frequently prescribed drug classes globally, but their misuse contributes significantly to antimicrobial resistance (AMR) and a high burden of adverse drug events (ADEs). Special populations including pediatric, geriatric and critically ill patients face unique risks due to altered pharmacokinetics and higher rates of polypharmacy. Research indicates that approximately 20% of hospitalized adults receiving systemic antibiotics experience at least one ADE, with geriatric patients accounting for nearly 45.6% of these cases. In pediatric populations, antibiotics are responsible for nearly half of all drug-related emergency department visits.
Drug utilization evaluations show a high prevalence of "Watch" group antibiotic use (Eg; Cephalosporins and Fluoroquinolones), which are frequently associated with serious side effects like skin rashes, gastrointestinal distress and nephrotoxicity. This review synthesizes current data on antibiotic consumption patterns using the WHO AWaRe framework and examines the severity and preventability of associated ADEs. The findings underscore the critical need for robust antimicrobial stewardship (AMS) and active Pharmacovigilance to mitigate risks in vulnerable cohorts and ensure patient safety.

Key Words:
Antimicrobial Stewardship; Adverse Drug Reactions (ADRs); Geriatric and Pediatric Pharmacotherapy; WHO AWaRe Classification; Drug Utilization Evaluation (DUE); Antimicrobial Resistance (AMR) and Pharmacovigilance.

Corresponding Author:
Dr. Purushothama Reddy K; E-mail: reddypharma6@gmail.com

Background

Antibiotic utilization among special populations requires careful dose adjustment and monitoring, as these groups are at significantly higher risk for adverse drug events (ADEs) due to altered drug metabolism and underlying co-morbidities. Antibiotic stewardship is essential for managing special populations, as physiological changes in geriatric, pediatric and critically ill patients significantly alter drug pharmacokinetics and increase the risk of adverse drug events (ADEs). Data suggests high utilization of broad-spectrum agents in these groups, with geriatric patients accounting for over 45% of antibiotic-related ADEs and antibiotics driving nearly 50% of pediatric emergency room visits. Targeted, organ-specific pharmacovigilance and structured antimicrobial stewardship programs (ASPs) are necessary to mitigate these risks.

Antibiotic utilization in special populations specifically the elderly, pediatrics and patients with renal/hepatic impairment is characterized by high consumption rates often coupled with irrational prescribing, leading to significant adverse drug events (ADEs). In these groups, Age-related pharmacokinetic (PK) and pharmacodynamic (PD) changes, polypharmacy and high comorbidity burden heighten the risk of severe, sometimes fatal, adverse events.

Search Strategy (Methods)

"A systematic search was performed across PubMed/MEDLINE, Scopus and Web of Science databases for articles published between 2014 and 2024. Keywords used included 'Antibiotic Utilization,' 'Adverse Drug Events,' 'Special Populations,' 'Pediatric Pharmacotherapy,' 'Geriatric Antibiotic Use' and 'WHO AWaRe.' Inclusion criteria focused on randomized controlled trials, systematic reviews and large-scale observational studies reporting incidence rates of ADEs and utilization metrics (Eg; DDD per 1000 inhabitants)."

Pharmacological and Clinical Rationale

The use of antibiotics in special populations specifically the pediatric, geriatric and critically ill presents a complex challenge for clinicians. Unlike the general adult population, these groups exhibit significant variations in pharmacokinetics (PK) and pharmacodynamics (PD).

Pediatric Population: Antibiotics constitute over one-third of prescriptions, with high usage of broad-spectrum agents. Studies show up to 85% of antibiotics are prescribed inappropriately to children in some settings, often for respiratory infections. Key risks include disruption of the microbiome, increased risk of allergic diseases (atopic dermatitis, asthma) and obesity.

Antibiotics cause nearly half of all drug-related emergency department visits for children. In infants (<1 year), the rate of ADEs per 10,000 prescriptions is the highest among all age groups. Specific risks include tooth discoloration (Tetracyclines) and potential cartilage damage (Fluoroquinolones).

Pediatric Considerations: Neonates and children are not "small adults." Their drug metabolism is governed by maturational changes in organ function, such as varying glomerular filtration rates (GFR) and hepatic enzyme activity. For instance, total body water is higher in infants, which increases the volume of distribution (V_d) for hydrophilic drugs like beta-lactams and aminoglycosides.

Geriatric Population (≥65 years): This group experiences the highest prevalence of antibiotic-related ADEs, accounting for approximately 45.6% of reported cases in some studies. This group receives a disproportionate number of antibiotics, often for prophylaxis or inappropriately for viral infections. Key risks include *Clostridioides difficile* infection (CDI), drug-induced delirium, renal toxicity (especially with Glycopeptides and Aminoglycosides) and severe cutaneous adverse reactions (cADRs), particularly with Sulfonamides and Cephalosporins, due to polypharmacy and impaired drug elimination.

Geriatric Considerations: Aging is associated with "inflammaging," increased frailty and progressive decline in renal and hepatic clearance. Elderly patients often present with multiple comorbidities, leading to polypharmacy and a heightened risk of drug-drug interactions (DDIs).

Critically Ill & Hospitalized Patients: Approximately 20% of hospitalized adults receiving antibiotics experience at least one ADE. Each additional day of therapy increases the odds of an ADE by roughly 4-7%.

In the intensive care unit (ICU), patients often experience capillary leak syndrome or receive aggressive fluid resuscitation, which drastically increases the V_d of hydrophilic antibiotics, often leading to sub-therapeutic dosing and the emergence of antimicrobial resistance (AMR).

Patients with Co-morbidities: Individuals with chronic kidney disease (CKD) or liver disease have a significantly higher risk for antibiotic-induced organ damage. For example, those with advanced cancer have a 35% chance of developing an ADE when exposed to antibiotics.

Chronic Kidney Disease (CKD): Inadequate dosing (both under- and overdosing) is common due to reliance on creatinine-based estimations, which overestimates renal function. This leads to increased toxicity (overdose) or treatment failure (underdose).

Liver Disease: Impaired metabolism of lipophilic drugs and hypoalbuminemia (increasing free fractions of drugs) makes patients with liver dysfunction, such as cirrhosis, highly susceptible to ADEs from commonly used antibiotics.

Risk Factors:

Polypharmacy: The risk of an ADR increases exponentially with the number of drugs; for example, from 13% with two medicines to 82% with seven or more.

Multiple Antibiotics: Taking more than one antibiotic concurrently doubles the risk of a serious ADR.

Inappropriate Prescribing: Roughly 50% of antibiotic prescriptions in pediatrics are estimated to be unnecessary or inappropriate, leading to avoidable toxicities.

Major Adverse Drug Event (ADE) Patterns

Cutaneous and Gastrointestinal: The skin and gastrointestinal systems are the most frequently affected, with rashes, pruritus and diarrhea being the most common ADRs.

Severe ADRs: These include acute renal failure (often with Aminoglycosides/Gentamicin), hepatotoxicity and severe skin reactions (Stevens-Johnson syndrome).

Neurotoxicity: β-lactams (like Cefepime), Carbapenems and Metronidazole are associated with neurotoxic effects, including encephalopathy and seizures, particularly in the elderly.

Antibiotic Class	Drug Examples	Common Adverse Events	Serious/Life-Threatening ADRs
Penicillins	Amoxicillin, Ampicillin, Piperacillin-Tazobactam	Diarrhea, nausea, mild skin rash.	Anaphylaxis, Drug-Induced Liver Injury (DILI), Interstitial Nephritis.
Cephalosporins	Ceftriaxone, Cefuroxime, Cefepime	Injection site pain, oral candidiasis.	*C. difficile* Associated Diarrhea (CDAD), Non-convulsive status epilepticus (Neurotoxicity).
Fluoroquinolones	Ciprofloxacin, Levofloxacin, Moxifloxacin	Dyspepsia, dizziness, photosensitivity.	Tendon rupture, Aortic aneurysm, QTc prolongation, Hypoglycemic coma.
Aminoglycosides	Gentamicin, Amikacin, Tobramycin	Headache, localized redness.	Irreversible Ototoxicity (Vestibular/Cochlear), Nephrotoxicity (Acute Tubular Necrosis).
Glycopeptides	Vancomycin, Teicoplanin	"Red Man Syndrome" (flushing), Chills.	Nephrotoxicity (dose-related), Ototoxicity, Neutropenia (rare).
Macrolides	Azithromycin, Clarithromycin, Erythromycin	Abdominal pain, GI hypermotility.	Torsades de Pointes (Sudden Cardiac Death), Cholestatic jaundice.
Tetracyclines	Doxycycline, Minocycline, Tigecycline	Heartburn, Nausea, Photosensitivity.	Pseudotumor cerebri, Hepatotoxicity, Permanent tooth staining in pediatrics.
Sulfonamides	Trimethoprim-Sulfamethoxazole (TMP-SMX)	Vomiting, Pruritus (itching).	Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Aplastic Anemia.
Oxazolidinones	Linezolid, Tedizolid	Diarrhea, Discoloration of tongue.	Myelosuppression (Thrombocytopenia), Serotonin Syndrome, Optic Neuropathy.
Nitroimidazoles	Metronidazole, Tinidazole	Metallic taste, Darkened urine.	Peripheral Neuropathy, Encephalopathy, Disulfiram-like reaction with alcohol.

Table 1: Detailed Profile of Antibiotic Classes, Agents and Adverse Drug Events (ADEs)

Special Population	Physiological Change	PK Impact	Antibiotic Examples
Pediatric (Neonates)	High total body water	Increased V_d (Hydrophilic)	Gentamicin, Amikacin
Geriatric	Decreased GFR/Renal blood flow	Reduced Clearance (C_l)	Vancomycin, Levofloxacin
Critically Ill	Capillary leak/Fluid over-load	Increased V_d	Piperacillin-Tazobactam
Elderly	Increased body fat %	Increased V_d (Lipophilic)	Macrolides, Fluoroquin-olones

Table 2: Pharmacokinetic Alterations and Clinical Implications

Population	Leading ADEs	Most Implicated Class	Incidence/Risk
Geriatric	Nephrotoxicity, GI distress	Cephalosporins, Fluoroquinolones	~45.6% of all ADE cases
Pediatric	Skin rashes, Diarrhea	Penicillins, Cephalosporins	19.9% overall harm rate
Hospitalized Adults	C. difficile, SJS/TEN	Sulfonamides, Clindamycin	20% experience ≥1 ADE

Table 3: Common Adverse Drug Events (ADEs) by Population

Utilization Patterns and the WHO AWaRe Framework

Current prescribing trends show an alarming reliance on the "Watch" group of antibiotics (Eg; Fluoroquinolones and 3rd generation Cephalosporins), which are broad-spectrum and carry higher risks for resistance and ADEs. In many tertiary care settings, the Access-to-Watch ratio is significantly below the WHO target of 0.60, indicating widespread use of high-risk agents where narrower-spectrum alternatives might suffice.

Discussion

Mitigating Risks through Precision Medicine - The high incidence of ADEs in special populations underscores the inadequacy of "one-size-fits-all" dosing. Precision medicine, through the integration of Therapeutic Drug Monitoring (TDM) and Pharmacogenomics (PGx), offers a pathway to optimize efficacy while minimizing toxicity.

1. Therapeutic Drug Monitoring (TDM) - TDM is the clinical practice of measuring drug concentrations at designated intervals to maintain a constant concentration in a patient's bloodstream. This is non-negotiable for antibiotics with a narrow therapeutic index.

2. Pharmacogenomics (PGx): Preventing Genetic Predispositions

Pharmacogenomics identifies genetic variations that influence drug response. In special populations, especially pediatrics, genetic screening can prevent irreversible, life-altering adverse events.

Aminoglycoside-Induced Hearing Loss: A specific mutation in the mitochondrial gene MT−RNR1 (specifically the m.1555A > G variant) predisposes individuals to profound, permanent deafness even after a single dose of gentamicin.

Hypersensitivity Reactions: Testing for the HLA−B*57:01 allele is now standard for Abacavir, but similar research is expanding into Sulfonamides and Penicillins to predict Stevens-Johnson Syndrome (SJS).

Antibiotic	Primary Toxicity Risk	TDM Goal	High-Risk Population
Vancomycin	Nephrotoxicity (AkI)	AUC/MIC ratio (400 – 600)	Critically ill, CKD patients
Aminoglycosides	Ototoxicity & Nephrotoxicity	Peak & Trough levels	Neonates, Cystic Fibrosis
Linezolid	Thrombocytopenia	Trough levels (<2 mg/L)	Geriatric (long-term use)
Voriconazole	Neurotoxicity/Hepatotoxicity	Trough levels (1 – 5 mg/L)	Hepatic impairment

Table 4: Antibiotics Requiring Routine TDM in Special Populations

3. Advanced Stewardship and Technology - Modern Antimicrobial Stewardship (AMS) programs are now utilizing technology to bridge the gap in clinical expertise.

Antibiotic Stewardship: Promoting shorter treatment courses as short as clinically possible is the most effective way to reduce the cumulative risk of ADEs.

Point-of-Care Testing (POCT): Utilizing rapid biomarkers like Procalcitonin (PCT) and C-reactive protein (CRP) to differentiate between bacterial and viral infections, thereby preventing unnecessary antibiotic exposure in pediatric and geriatric patients.

AI-Driven Dosing: Software (Eg; InsightRX, DoseMeRx) uses Bayesian forecasting to predict the best dose for a specific patient based on their age, weight and renal function in real-time.

Summary of Findings

ADR Incidence: Studies report ADR incidence rates for antibiotics to be roughly 14–16% among hospitalized patients.

Highest Risk Antibiotics: Cephalosporins, Fluoroquinolones and β-lactam combinations are frequently cited as causing the highest rates of ADRs in these populations.

Conclusion: Regular monitoring for early detection of ADEs and strict adherence to guidelines can prevent a significant percentage of antibiotic-related hospital admissions.

Strategy	Mechanism	Level of Evidence	Primary Benefit
TDM	Real-time dose titration	High (Standard of Care)	Prevents dose-dependent organ toxicity.
Pharmacogenomics	Genetic screening	Moderate (Emerging)	Prevents idiosyncratic reactions (Eg; deafness).
Procalcitonin Guided	Biomarker monitoring	Moderate	Reduces total duration of antibiotic exposure.
AWaRe Framework	Regulatory oversight	Administrative	Decreases use of high-risk "Watch" antibiotics.

Table 5: Summary of Preventative Strategies

Antibiotic Class	Primary Mechanism of Toxicity	Notable Adverse Drug Events (ADEs)	High-Risk "Special" Population
Penicillins	Immune-mediated hypersensitivity	Anaphylaxis, interstitial nephritis, and drug-induced liver injury (DILI) (esp. Amoxicillin-Clavulanate).	**Pediatrics:** Highest cause of allergic cutaneous eruptions.
Cephalosporins	Disruption of microbiome & Cross-reactivity	*C. difficile* infection (CDI), biliary sludging (Ceftriaxone) and seizures at high doses.	**Geriatrics:** Increased risk of CDI and neurotoxicity in renal impairment.
Fluoroquinolones	Connective tissue & CNS interference	Tendon rupture, aortic aneurysm, QTc prolongation and dysglycemia.	**Geriatrics:** High risk for delirium and tendon injury. **Pediatrics:** Arthropath y concerns.
Aminoglycosides	Mitochondrial & Renal tubule damage	Irreversible ototoxicity (hearing loss/vertigo) and acute tubular necrosis (ATN).	**Neonates:** Genetic susceptibility (MT-RNR1). **Critically Ill:** AKI risk.
Glycopeptides (Eg; Vancomycin)	Direct cellular toxicity & Histamine release	Nephrotoxicity and "Red Man Syndrome" (infusion-related reaction).	**Critically Ill:** High incidence of AKI when combined with Piperacillin-Tazobactam.
Tetracyclines	Calcium chelation & GI irritation	Tooth enamel hypoplasia, photosensitivity and esophageal ulceration.	**Pediatrics (<8 yrs):** Risk of permanent tooth discoloration.
Sulfonamides	Folate synthesis inhibition	Stevens-Johnson Syndrome (SJS/TEN) and crystalluria.	**HIV/ Immunocompromise d:** Significantly higher rates of severe cutaneous reactions.
Macrolides	Cardiac ion channel blockade	GI hypermotility, QTc prolongation and cholestatic hepatitis.	**Geriatrics:** Fatal arrhythmias when co-administered with CYP3A4 inhibitors.
Oxazolidinones (Eg; Linezolid)	Mitochondrial protein inhibition	Thrombocytopenia, lactic acidosis and serotonin syndrome.	**Geriatrics:** Hematologic toxicity increases after 14 days of therapy.

Table 6: Comprehensive Adverse Event Profiles by Antibiotic Class

Conclusion and Future Directions

The utilization of antibiotics in special populations remains a double-edged sword. While these agents are lifesaving, the risk of Adverse Drug Events (ADEs) is disproportionately high in pediatric, geriatric and critically ill cohorts due to distinct physiological vulnerabilities. Current patterns reveal a concerning over-reliance on "Watch" category antibiotics, which exacerbates both individual toxicity and global resistance.

Moving forward, the integration of Precision Antimicrobial Stewardship is essential. This includes the universal adoption of Therapeutic Drug Monitoring (TDM) for drugs with narrow therapeutic windows and the implementation of Point-of-Care Pharmacogenomic testing to prevent irreversible toxicities like aminoglycoside-induced ototoxicity. Future research should prioritize the development of AI-driven dosing algorithms tailored specifically to patients with multi-organ dysfunction to ensure that the goal of "First, Do No Harm" is maintained in antimicrobial therapy.

References

1. World Health Organization. The 2024 WHO AWaRe classification of antibiotics for

evaluation and monitoring of use. Geneva: World Health Organization; 2024.

2. Tamma PD, et al., Antimicrobial Stewardship and Patient Safety. Infectious Disease Clinics of North America, 2019; 33 (3): 617 - 633.
3. Lidster J, et al., Antibiotic-associated adverse drug events in hospitalized patients. JAMA Internal Medicine, 2017; 177 (9): 1381 - 1383.
4. Poliseno V, et al., Adverse drug reactions in the pediatric population: A systematic review. Clinical Epidemiology and Global Health, 2024; 26: 101538.
5. Beovic B, et al., Antibiotic use and resistance mechanisms: Trends and preventive strategies. International Journal of Pharmaceutical Sciences and Research (IJPSR), 2023; 15 (4): 112 - 120.
6. Giannini A, et al., Pharmacokinetics/ Pharmacodynamics of Antibiotics in Critically Ill Patients. Clinical Pharmacokinetics, 2020; 59: 159 - 175.
7. Zhu X, et al., Adverse drug reactions of antibiotics in the elderly: A retrospective study. International Journal of Pharmaceutical Sciences Review and Research, 2023; 84 (1): 45 - 51.
8. He P, et al., Therapeutic Drug Monitoring of Vancomycin: A Guideline Revised. American Journal of Health-System Pharmacy, 2020; 77 (11): 835 - 864.
9. McDermott JH, et al., Rapid Point-of-Care Genotyping to Prevent Aminoglycoside-Induced Ototoxicity. JAMA Pediatrics, 2022; 176 (5): 486 - 492.
10. Asseray N, et al., Frequency and severity of adverse drug reactions due to antibiotics in emergency departments. Journal of Egyptian Public Health Association, 2021; 96: 15.
11. Goud SM, et al., Drug utilization evaluation of antibiotics in a tertiary care hospital. Journal of Pharmaceutical Care & Health Systems, 2023; 10 (2): 1 - 6.
12. Muller AE, et al., The role of TDM in optimizing antibiotic therapy in the ICU. Antibiotics (Basel). 2020; 9 (11): 756.
13. Platts-Mills TF, et al., Antibiotic Use and the Risk of C. difficile in Older Adults. Biomedical and Pharmacology Journal (BPJ), 2017; 10 (1).
14. Simoes AS, et al., The AWaRe classification as a tool for antimicrobial stewardship. Front Antibiotics. 2025; 4: 1578217.
15. Hicks LA, et al., US Outpatient Antibiotic Prescribing Variation. Clinical Infectious Diseases, 2021; 72 (10): e523 - e531.
16. Jha RK, et al., Exploring antibiotic safety: A prospective observational study of adverse drug reactions from a tertiary care center in Bihar, India. Clinical Epidemiology and Global Health (CEGH), 2024; 26: 101538.
17. Fujii S, et al., Retrospective study on penicillin allergy delabeling and evaluation of an antibiotic allergy assessment tool. The Journal of Infection and Chemotherapy (JIC), 2025; 31 (1): 15 - 22.
18. Ruiz J, et al., Antimicrobial Pharmacokinetics and Pharmacodynamics in Critically Ill Patients Who Are at Risk of Not Achieving the Target Concentration. Antibiotics (Basel). 2023; 12 (3): 477.
19. Anandhkumar S, et al., A Study on Antibiotics Usage Trends: Insights from Drug Utilization Evaluation. International Journal of Pharmaceutical Sciences and Research (IJPSR), 2025; 17 (8): 45 - 53.
20. Mohammed A, et al., Assessment of Adverse Drug Reactions in Geriatric Patients Admitted to a Tertiary Care Teaching Hospital in South India. REDVET. 2024; 25 (3): 142 - 150.
21. Adane M, et al., Antimicrobial Use-Related Problems Among Hospitalized Pediatric Patients at a Specialized Tertiary Care Hospital. Infection and Drug Resistance, 2024; 17: 155 - 168.
22. Gyamfi E, et al., Antibiotic Use in Pediatric Care in Ghana: A Call to Action for Improved Stewardship. Antibiotics (Basel). 2025; 14 (8): 779.
23. Elsayed A, et al., Patterns of antibiotic use, knowledge and perceptions among clinicians in Jordan. Saudi Pharmaceutical Journal, 2022; 30 (3): 215 - 223.
24. Cunha BA., Antibiotic side effects: A clinical approach to minimize patient harm. Medical Clinics of North America, 2021; 105 (2): 315 - 334.
25. imoes AS, et al., The AWaRe classification as a tool for antimicrobial stewardship in low-resource settings. Front Antibiotics, 2025; 4: 1578217.

The World Journal of Medical Education & Research (WJMER) is the online publication of the Doctors Academy Group of Educational Establishments. It aims to promote academia and research amongst all members of the multi-disciplinary healthcare team including doctors, dentists, scientists, and students of these specialties from all parts of the world. The journal intends to encourage the healthy transfer of knowledge, opinions and expertise between those who have the benefit of cutting-edge technology and those who need to innovate within their resource constraints. It is our hope that this interaction will help develop medical knowledge & enhance the possibility of providing optimal clinical care in different settings all over the world.

WJMER

World Journal of Medical Education and Research

An Official Publication of the Education and Research Division of Doctors Academy

9 789380 573977